Novartis AG Q3 2025 Earnings Recap

NOVN.SW Q3 2025 October 28, 2025

Get alerts when NOVN.SW reports next quarter

Novartis posted strong Q3 2025 results, bolstered by 7% sales growth and key pipeline advancements, sustaining momentum across multiple therapeutic areas.

Earnings Per Share Miss

$1.81 vs $1.83 est.

-1.1% surprise

Revenue Beat

11422076160 vs 11168157203 est.

+2.3% surprise

Market Reaction

1-Day -4.16%

5-Day -3.77%

30-Day -0.16%

See NOVN.SW alongside your other holdings

Add to your portfolio — free

Key Takeaways

Sales and core operating income each increased by 7%, with core operating margin at 39.3%.
Kisqali led the charge with a 68% sales increase, driven by strong early breast cancer uptake, marking significant market leadership.
Noteworthy pipeline achievements include FDA approval of Rhapsido and positive Phase III data for Ianalumab, Pluvicto, and Cosentyx.
Kesimpta saw robust 44% growth in Q3, indicating strong demand, especially in first-line therapy, across global markets.
Pluvicto accelerated by 45% in constant currencies, strengthened by a new approval for pre-taxane castrate-resistant prostate cancer.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit NOVN.SW on AllInvestView.